Denemek ALTIN - Özgür

PROSOLV® 730: Directly compressible carrier for lipophilic ingredients

Express Pharma

|

November 2025

Nearly 90 % of molecules in the discovery pipeline and 40 % of drugs with market approval are poorly water soluble. Poor aqueous solubility can lead to low bioavailability resulting in insufficient plasma levels. Oil-based preparations of these APIs, as well as oily APIs in general, present challenges in terms of solid dosage form manufacturing. PROSOLV® 730 was designed to provide a solution to the formulation of BCS class II and IV APIs. It enables the formulation of lipidic APIs or API-loaded lipid systems by facilitating the adsorption of oil, creating a free-flowing, compactible system that can be further formulated. PROSOLV® 730 is a co-processed, high-functionality excipient comprising MCC SILICA COPOVIDONE

- Mr. Suyesh Kale

Nearly 90% of molecules in the discovery pipeline and 40% of drugs with market approval are poorly water soluble.

Poor aqueous solubility can lead to low bioavailability resulting in insufficient plasma levels.

Oil-based preparations of these APIs, as well as oily APIs in general, present challenges in terms of solid dosage form manufacturing.

PROSOLVⓇ 730 was designed to provide a solution to the formulation of BCS class II and IV APIs. It enables the formulation of lipidic APIs or APIloaded lipid systems by facilitating the adsorption of oil, creating a free-flowing, compactible system that can be further formulated.

PROSOLV® 730 is a coprocessed, high-functionality excipient comprising MCC SILICA COPOVIDONE

Specific surface area

PROSOLV 730 presents a 70 plus times greater specific surface area than Microcrystalline Cellulose.

Physical Properties of PROSOLV® 730

  • High oil binding capacity

  • White, free-flowing powder

  • Chemically inert

  • Non-soluble

  • Excellent compactability

  • Enhanced lubrication efficiency

  • Improved blending properties

  • Over 70 times greater specific surface area than regular Microcrystalline Cellulose (MCC)

  • Coprocessed excipient with no chemical bonding between ingredients

Express Pharma'den DAHA FAZLA HİKAYE

Express Pharma

Express Pharma

Speed and flexibility play a critical role in how we compete with larger global players

Kriti Jajoo, VP-BD and Strategy, Shriji Polymers, as the next-gen leader, speaks on how the company is evolving with a leadership approach that balances technology, sustainability, and customer-centricity to create long-term value, in an interview with Express Pharma

time to read

6 mins

January 2026

Express Pharma

Express Pharma

Vizag rising: Shaping India's pharma future

At the Vizag Pharma Summit 2025, hosted by Express Pharma, industry leaders discussed how quality, R&D, compliance, and emerging technologies are driving India's next phase of pharma growth

time to read

9 mins

January 2026

Express Pharma

Express Pharma

Future of pharma: Trends, challenges & AI

Industry experts discussed how Al is transforming pharmaceutical R&D, highlighting both the promise and the practical limitations of current technologies

time to read

2 mins

January 2026

Express Pharma

Express Pharma

Gandhi Automations presents multi-composites, high-performance door PRIME NEO for clean environments

When it comes to pharmaceutical facilities and laboratories, clean rooms' hygiene and protection from environmental contamination are the most important factors to consider.

time to read

1 mins

January 2026

Express Pharma

Express Pharma

Can Indian biosimilars and generics restate accessibility in global underserved markets?

Hari Kiran Chereddi, MD & CEO - HRV Pharma & NHG Pharma highlights that India's success in generics is no longer enough, as the world now demands advanced biologics, biosimilars, and personalised medicines. He further emphasises on the need for stronger regulation, innovation, and investment so India can lead in next-generation therapies and expand global access to cutting-edge healthcare

time to read

3 mins

January 2026

Express Pharma

Express Pharma

The next wave of growth will belong not to the fastest manufacturers but to the most innovative problem-solvers

As India moves into 2026, industry experts state that the next phase of growth in pharmaceuticals will depend on strengthening formulation R&D, building a skilled and adaptable workforce, and closing gaps between academic research and industry needs.

time to read

6 mins

January 2026

Express Pharma

Express Pharma

Results win customers. Leadership discipline keeps them

Drawing themes from his new book The Dual Mandate in B2B - Driving Results. Shaping Culture, Mohan Joshi - Global C-Suite Partner & Former President, SCHOTT India, discusses leadership systems, alignment, and execution in conversation with Neha Aathavale.

time to read

3 mins

January 2026

Express Pharma

Express Pharma

INDIA'S INNOVATION JOURNEY FROM PROMISE TO PROOF

India's pharma ecosystem is ready to embrace stronger science and bolder ideas. Turning early breakthroughs into scalable, sustainable innovation remains the challenge

time to read

8 mins

January 2026

Express Pharma

Express Pharma

PRUV® -The original Sodium Stearyl Fumarate

JRS Pharma's PRUV® is the original sodium stearyl fumarate (SSF) introduced in the market over 20 years ago

time to read

5 mins

January 2026

Express Pharma

Express Pharma

Odisha's pharma pitch

The inaugural Odisha Pharma Summit 2025 delivered strong early signals of intent, positioning the state as an upcoming destination for PLI-triggered expansions, to complement existing pharma hubs. As Hemant Sharma, ACS Industry Dept and I&PR Dept, Govt of Odisha puts it, the aim is to “become a good, viable second option.” How fast can the eastern newcomer catch up and become India's next life sciences hub, asks Viveka Roychowdhury

time to read

5 mins

January 2026

Listen

Translate

Share

-
+

Change font size